Vilaseca Marina, Guixé-Muntet Sergi, Fernández-Iglesias Anabel, Gracia-Sancho Jordi
Hepatic Hemodynamic Laboratory, IDIBAPS Biomedical Research Institute, Barcelona, Spain.
Department of Biomedical Research, University of Bern, Bern, Switzerland.
Therap Adv Gastroenterol. 2018 Nov 25;11:1756284818811294. doi: 10.1177/1756284818811294. eCollection 2018.
Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated by a paradoxical increase in portal blood inflow. Although extensive preclinical and clinical research in the field has been developed in recent decades, no effective treatment targeting its primary mechanism has been defined. The present review critically summarizes the current knowledge in portal hypertension therapeutics, focusing on those strategies driven by the disease pathophysiology and underlying cellular mechanisms.
门静脉高压是慢性肝病的主要临床后果之一，对患者的预后和生存有着深远影响。其病理生理学将肝内血管阻力的病理性增加定义为其发展的主要因素，随后门静脉血流的反常增加会使其进一步加重。尽管近几十年来该领域已开展了广泛的临床前和临床研究，但尚未确定针对其主要机制的有效治疗方法。本综述批判性地总结了门静脉高压治疗学的当前知识，重点关注那些由疾病病理生理学和潜在细胞机制驱动的策略。
